论文部分内容阅读
目的:研究各级宫颈上皮内瘤变(CIN)及宫颈癌组织中E-cadherin的表达及其与高危型人乳头瘤病毒(high risk human papillomavirus,HR-HPV)感染的相关性探讨其在宫颈疾病发生、发展中的意义。方法:选取2008年1月至2014年12月我院收治的150例患者标本并将其分为CINⅠ级组、CINⅡ-Ⅲ级组及宫颈癌组用免疫组化法对E-cadherin的表达情况进行检测并于术前采用PCR-反向点杂交法检测患者高危型HPV感染情况所得结果:进行统计学分析。结果:(1)E-cadherin在CINⅠ级、CINⅡ-Ⅲ级及宫颈癌中的阳性表达率分别为40/50(80.0%),24/50(48.0%)、17/50(34.0%),随疾病的进展E-cadherin的表达明显减少,各组间差异有统计学意义(P<0.05)。(2)高危型HPV在CINI级、CINⅡ-Ⅲ级及宫颈癌中的阳性感染率分别为21/50(42.0%)、38/50(76.0%),48/50(96.0%),各组间差异有统计学意义(P<0.05)。(3)在CIN和宫颈癌中,HR-HPV阳性组中E-cadherin阳性率39.3%(42/107)低于HR-HPV阴性组中E-cadherin阳性率90.7%(39/43)(P<0.05)。结论:E-cadherin的表达下降或缺失可能是HR-HPV导致宫颈癌发生、发展的机制之一。
Objective: To investigate the correlation between the expression of E-cadherin and high risk human papillomavirus (HR-HPV) in cervical intraepithelial neoplasia (CIN) and cervical cancer at all levels, The occurrence of disease, the significance of the development. Methods: 150 patients from January 2008 to December 2014 in our hospital were selected and divided into CIN Ⅰ group, CIN Ⅱ-Ⅲ group and cervical cancer group by immunohistochemistry for the expression of E-cadherin To detect and preoperative use of PCR-reverse dot hybridization detection of high-risk HPV infection in patients with the results obtained: a statistical analysis. Results: (1) The positive rates of E-cadherin in CINⅠ, CINⅡ-Ⅲlevel and cervical cancer were 40/50 (80.0%), 24/50 (48.0%), 17/50 The expression of E-cadherin was significantly decreased with the progress of the disease, with significant differences among the groups (P <0.05). (2) The positive infection rates of high-risk HPV in CINI grade, CINⅡ-Ⅲ grade and cervical cancer were 21/50 (42.0%), 38/50 (76.0%) and 48/50 (96.0% The difference was statistically significant (P <0.05). (3) In CIN and cervical cancer, the positive rate of E-cadherin in HR-HPV positive group was 39.3% (42/107), which was lower than that in HR-HPV negative group (90.7%, P <0.05). Conclusion: The decreased or absent expression of E-cadherin may be one of the mechanisms that cause the development of cervical cancer by HR-HPV.